The AT1R gene is composed of five exons located on chromosome 3q, where the first four exons encode the 5′-untranslated region (5′-UTR). A polymorphism in the 3′-UTR of the AT1R gene leads to the transfer of adenine (A) to cytosine (C) base at the 1166 position. 16, 17 The AT1R gene plays an important role in the pathogenesis of breast cancer and the cardiovascular system. 18, 19 Several studies have suggested that AT1R A1166C gene polymorphism is associated with breast cancer risk and prognosis, 13, 15, [20] [21] [22] while other studies have shown no significant association with breast risk. 23, 24 In 2010, Xi et al. performed a metaanalysis and found that AT1R A1166C polymorphisms might be implicated in the pathogenesis of breast cancer. 25 However, Xi et al.'s conclusion was limited by the small sample size (only two publications included). Therefore, we performed an update meta-analysis to further clarify the relationship between AT1R A1166C polymorphism and breast cancer risk.
Materials and methods

Literature identification
To identify all the articles that reported the association of AT1R A1166C polymorphisms with breast cancer risk, we conducted a computerized literature search of PubMed, EMBase, Chinese Biomedical Literature Database, Chinese CNKI, Web of Science, and the Wanfang database using the terms "breast cancer (Mesh)," "angiotensin II type 1 receptor" or "AT1R," "polymorphism" or "SNP," "genotype," or "variation" without any restriction on language or publication year. By means of online retrieval and literature review, references obtained using the above-mentioned databases were reviewed again to ensure that no relevant studies were missed.
All the included studies had to meet the following inclusion criteria: (1) independently published case-control or cohort studies on the relation between AT1R polymorphism and breast cancer; (2) similar themes and methods; (3) the genotype data available. We excluded the literature in which the relevant data are not available or there is heterogeneity of gene polymorphism in the control population.
Quality assessment and data extraction
Two reviewers (Fangguo Chen and Guiling Chen) independently evaluated the studies and extracted the data using a standard approach according to the above-mentioned inclusion criteria. Discrepancies were resolved through discussion. The Cochrane Handbook 5.2 quality evaluation criteria were utilized to assess the methodological quality of included studies. Literature that had been reported repeatedly or poor-quality literature were excluded from the included studies.
For each study, we extracted the first author's last name, year of publication, ethnicity of participants, numbers of cases and controls, and frequency of AA, AC, and CC genotypes. The Hardy-Weinberg equilibrium was assessed using the χ 2 test.
Statistical analysis
We performed the meta-analyses utilizing RevMan 5.2 software. Both Q-test and I 2 test were directly utilized to examine the heterogeneity between each study. The association between A1166C polymorphisms of the AT1R gene and the risk of breast cancer was estimated by calculating pooled odds ratio (OR) and 95% confidence interval (CI). The significance of the pooled OR was determined by Z test (p < 0.05 was considered statistically significant). A random-or fixed-effects model was used to calculate pooled effect estimates in the presence (p < 0.10) or absence (p > 0.10) of heterogeneity, respectively. Subgroup analyses were performed according to ethnicity. Sensitivity analysis was performed to evaluate the stability of the results by removing one single study from the overall pooled analysis each time to check the influence of the removed data set to the overall ORs. Publication bias was assessed by RevMan 5.2 statistical software to make the funnel plot. A P < 0.05 was considered as a significant difference.
Results
Study identification
As shown in Figure 1 , 48 literature studies were preliminarily detected; 42 of these were excluded as being obviously irrelevant from reading their titles and abstracts. Thus, six articles met the inclusion criteria. However, the study by Koh et al. was excluded because it examined the associations of three AT1R polymorphisms (namely A168G, C535T, and T825A) rather than A1166C polymorphism. 26 Therefore, five studies with a total of 972 patients with breast cancer and 1336 cancer-free control subjects were included in this research. 15, [20] [21] [22] [23] Four of these studies were performed in a Caucasian population, 15, 20, 22, 23 while only one study was conducted in a Chinese population. 21 The characteristics of the studies included are shown in Table 1 .
Association of A1166C polymorphism and breast cancer risk
The results of meta-analysis of the association between breast cancer and AT1R gene polymorphism in five casecontrol studies are shown in Figures 2 and 3 . The heterogeneity test of the various studies revealed heterogeneous results ((AC+CC) vs. AA: I 2 = 85%, p < 0.0001; C allele vs. A allele: I 2 = 85%, p < 0.0001); therefore, we used the random-effects model in the analysis. However, we did not find heterogeneity between each study in a dominant model (AA+AC vs. CC: I 2 = 44%, p = 0.13); thus we used the fixed-model to merge the OR value. In all studies, including Caucasian and Asian populations, we did not find an association between A1166C polymorphism and breast cancer in any genetic model ((AC+CC) vs. AA: OR = 0.97, 95% CI: 0.54-1.72, p = 0.91; (AA+AC) vs. CC: OR = 1.24, 95% CI: 0.76-2.01; C allele vs. A allele: OR = 0.95, 95% CI: 0.58-1.54, P = 0.83; Figure 2 ). Subgroup analysis according to ethnicity suggested that A1166C polymorphism was associated with decreased risk for breast cancer in Caucasian populations in an additive model (C vs. T: OR = 0.77, 95% CI: 0.62-0.96, p = 0.02). However, we did not find association in other genetic models (AC+CC vs. AA: OR = 0.78, 95% CI: 0.50-1.22; CC vs. AA+AC: OR = 1.64, 95% CI: 0.94-2.85) in Caucasian populations (Figure 3 ).
Publication bias analysis
The result of Egger's test did not show statistical evidence for bias (data not shown). This indicates that there is no publication bias, and the result of the study is credible.
Sensitivity analysis
We deleted one single study from the overall pooled analysis each time to check the influence of the removed data set to the overall ORs. The pooled ORs and 95% CIs were not significantly altered when any part of the study was omitted, which indicated that any single study had little impact on the overall ORs. 
Discussion
In the present study, we performed a meta-analysis to evaluate the association of AT1R gene A1166C polymorphism with breast cancer. We found C allele carriers have a lower risk for breast cancer in Caucasian populations. This study is an update meta-analysis in which the results were different from the previous one. 25 Previous studies suggested that the RAS plays an important role in the regulation of cell proliferation, angiogenesis, and inflammation, 27, 28 which indicated that RAS genes might be implicated in the carcinogenesis.
AT1R not only has an important role in the regulation of blood pressure and cardiovascular homeostasis, 29, 30 but also influences tumor cell proliferation, migration, angiogenesis, and inflammation. 31, 32 Recently, a SNPs A1166C polymorphism was reported to be associated with the risk for breast cancer. 15, 21, 22 However, the results were inconsistent between each study.
One published meta-analysis including only two casecontrol studies showed a significant association between AT1R polymorphism and breast cancer risk. 25 However, there are several studies that had not been included in their meta-analysis. In the present study, we included five case-control studies to perform a meta-analysis. The results suggested that the AT1R 1166C allele is a protective factor for breast cancer in Caucasian populations. However, we did not find that the 1166CC genotype was associated with reduced risk for breast cancer. Since only one study was conducted in an Asian population, 21 we did not include this study in the subgroup analysis. This fact may be a limitation of our study.
In conclusion, the present study suggests that the 1166C allele of the AT1R gene is associated with reduced risk for breast cancer in Caucasian populations. However, there is still a need for further research and screening of etiological relations between the functional polymorphism loci of the AT1R gene and the susceptibility of breast cancer.
